Jumping Off Fence, CombiMatrix Decides to Enter Developing Protein Array Marketplace | GenomeWeb

CombiMatrix is working on a protein array, the company's first, BioArray News has learned.

The company had previously considered developing protein arrays, but found that cross-reactivity between the antibodies and the sample made it impossible to put more than 100 antibodies on the array and achieve good performance. Customers, the company believed, would not be willing to pay a premium price for these arrays.

CombiMatrix now thinks its improved technology can overcome this challenge.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.